Stocks Health care XNCR
NASDAQ · Health careXencor Inc (XNCR)
Xencor Inc brought in $200.5M of revenue over the twelve months to September 30, 2026, up 33.5% from a year earlier. It posted a net loss of $117.9M. In fiscal 2025 capital spending exceeded operating cash flow by $138.3M. At September 30, 2026 it held $59.6M in cash against $71.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Xencor Inc
- Net worth
- Xencor Inc has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $560.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $125.6M (+13.7% year on year), with a net loss of $91.9M. Over the 12 months to September 30, 2026: revenue $200.5M, net loss $117.9M.
- Cash flow
- In fiscal 2025 operations used $135.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Xencor Inc's next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Xencor Inc does
Xencor Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker XNCR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $125.6M | -$91.9M | -$1.24 | -$138.3M |
| 2024 | $110.5M | -$232.6M | -$3.58 | -$208.3M |
| 2023 | $174.6M | -$133.1M | -$2.20 | -$96.4M |
| 2022 | $164.6M | -$55.2M | -$0.93 | -$14M |
| 2021 | $275.1M | $82.6M | $1.37 | -$30.2M |
| 2020 | $122.7M | -$69.3M | -$1.21 | -$15.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where XNCR ranks in Health care
Latest SEC filings
What Xencor Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Passive stake changed SCHEDULE 13G/A
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 455% to $116.5M versus the same quarter last year; diluted EPS $0.50 versus -$0.08.
- November 4, 2026
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 26, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 17% to $51.2M versus the same quarter last year; diluted EPS -$0.29 versus -$0.41.
- August 5, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026
Insider trades
What the people running Xencor Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 18, 2026 | Feigal EllenDirector | Soldpre-planned (10b5-1) | 6,843 | $89.4K |
| June 16, 2026 | Gorman Kevin CharlesDirector | Received as pay | 10,302 | - |
| June 16, 2026 | Simpson Todd EDirector | Received as pay | 10,302 | - |
| June 16, 2026 | Ranieri Richard JDirector | Received as pay | 10,302 | - |
| June 16, 2026 | Montgomery Alan BruceDirector | Received as pay | 10,302 | - |
| June 16, 2026 | Gustafson Kurt ADirector | Received as pay | 10,302 | - |
| June 16, 2026 | Klencke BarbaraDirector | Received as pay | 10,302 | - |
| June 16, 2026 | Feigal EllenDirector | Received as pay | 10,302 | - |
Who owns XNCR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Primecap Management Co13G, passive | 14.79% | August 14, 2025 |
| BlackRock, Inc.13G, passive | 14.5% | October 27, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 9.99% | February 17, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 8.7% | November 14, 2025 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 6.5% | March 30, 2026 |
| Vanguard Capital Management13G, passive | 5.13% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 208 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 13,651,261 | +615,343 |
| Primecap Management Co | 10,181,322 | -156,700 |
| Bvf Inc | 7,133,720 | 0 |
| Rtw Investments, LP | 6,777,461 | 0 |
| RA Capital Management, L.P. | 5,274,274 | +377,037 |
| State Street Corp | 4,954,016 | +601,980 |
| Vanguard Capital Management LLC | 3,278,802 | +177,155 |
| TCG Crossover Management, LLC | 2,452,138 | 0 |
| Vanguard Portfolio Management LLC | 2,215,690 | -1,284,652 |
| Geode Capital Management, LLC | 1,920,859 | +105,282 |
| Morgan Stanley | 1,752,556 | +194,266 |
| UBS Group AG | 1,306,174 | +223,755 |
| Baker Bros. Advisors LP | 1,102,106 | 0 |
| Legal & General Group Plc | 1,091,177 | +24,397 |
| Dimensional Fund Advisors LP | 1,011,119 | -283,768 |
| Goldman Sachs Group Inc | 968,778 | +204,985 |
| Millennium Management LLC | 853,677 | +243,889 |
| Two Sigma Investments, LP | 819,515 | +14,094 |
| Northern Trust Corp | 794,279 | +49,760 |
| Johnson & Johnson | 748,062 | 0 |
Insiders
12 insiders reported holding 1,136,118 shares in total, about $43.8M at the last price.
| Holder | Shares |
|---|---|
| Dahiyat Bassil IPRESIDENT & CEO, Director | 546,316 |
| Desjarlais John RSR. VICE PRESIDENT & CSO | 263,831 |
| Eckert CeliaSVP, GENERAL COUNSEL | 76,918 |
| Cornelissen Bart JanSR. VICE PRESIDENT & CFO | 75,898 |
| Klencke BarbaraDirector | 29,974 |
| Montgomery Alan BruceDirector | 25,849 |
| Gustafson Kurt ADirector | 25,011 |
| Ranieri Richard JDirector | 24,011 |
| Simpson Todd EDirector | 23,988 |
| Gorman Kevin CharlesDirector | 21,680 |
Questions about XNCR
What does Xencor Inc do?
Xencor Inc is a company in the Health care sector, listed on NASDAQ as XNCR. Its shares trade on NASDAQ under the ticker XNCR.
What is Xencor Inc's net worth?
Xencor Inc has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $560.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Xencor Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $117.9M on revenue of $200.5M.
How much revenue does Xencor Inc make?
Over the twelve months to September 30, 2026 Xencor Inc reported revenue of $200.5M. That is 33.5% more than a year earlier.
When did Xencor Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 6, 2026.
When is Xencor Inc's next earnings report?
Xencor Inc's next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare XNCR with
Follow XNCR
Get an email when Xencor Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Xencor Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.